ERYP Erytech Pharma S.A.

8.31
-0.08  -1%
Previous Close 8.39
Open 8.31
Price To Book 0.81
Market Cap 149060916
Shares 17,937,535
Volume 153
Short Ratio
Av. Daily Volume 3,235

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial completed.
Hydro-Lido
Hemorrhoids
Phase 3 enrollment to commenced soon - noted September 10, 2018.
Eryaspase (GRASPA)
Pancreatic cancer
Upcoming meeting with FDA to discuss next steps.
Eryaspase (GRASPA)
Acute lymphoblastic leukemia (ALL) - front line
Phase 2 enrolment to commence early 2019. Interim data due 2H 2019.
Eryaspase (GRASPA)
Triple-Negative Breast Cancer (TNBC)
Phase 2b planned for 1H 2019.
Eryaspase (GRASPA)
Pancreatic cancer - first-line